SIGN UP
LOG IN
MARKET
BLRX
BLRX
Biolinerx
NASDAQ
1.590
+0.010
+0.63%
Opening 10:43 12/06 EST
OPEN
1.580
PREV CLOSE
1.580
HIGH
1.620
LOW
1.580
VOLUME
32.62K
TURNOVER
0
52 WEEK HIGH
2.530
52 WEEK LOW
0.5450
MARKET CAP
114.81M
P/E (TTM)
-1.8688
1D
5D
1M
3M
1Y
5Y
BioLineRx: Still A Buy, With Some Questions
Biolinerx gained approval for a blood cancer drug that aids in stem cell transplantation. Motixafortide, the flagship drug, shows promising results in mobilizing blood stem cells and in combination with other treatments for pancreatic cancer. The company has a limited amount of cash on hand but has secured a licensing deal.
Seeking Alpha · 1d ago
Weekly Report: what happened at BLRX last week (1127-1201)?
Weekly Report · 2d ago
BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges
Biolinerx ltd. Is a biopharmaceutical company specializing in cancer and rare disease therapies. The company's main product, aphexda, was fda-approved for stem cell mobilization in multiple myeloma patients. Biolinerx's low cash reserves and need for additional financing pose risks, but its valuation appears relatively conservative.
Seeking Alpha · 3d ago
Weekly Report: what happened at BLRX last week (1120-1124)?
Weekly Report · 11/27 10:23
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
Benzinga · 11/20 17:37
Bioline RX Receives Buy Rating Despite Lower Than Expected Q3 Results: Expansions, Partnerships, and Promising Clinical Trials Signal Future Growth
TipRanks · 11/20 17:35
Biolinerx: Report of foreign issuer
Press release · 11/20 14:01
LRHC, SGD and NSTG among pre-market losers
Syntec optics holdings (optx) -15%; plus therapeutics (pstv) reports new interim respect-gbm phase 2 trial data at the society for neurooncology annual meeting. Lrhc, sgd and nstg among pre-market losers.
Seeking Alpha · 11/20 13:24
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Webull offers BioLine RX Ltd - ADR stock information, including NASDAQ: BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.